NorthWest Biotherapeutics Inc (NWBO)

[survivor1x]

CLDX have/had AF gushing all over them. That was of course before the final results of Rindo came out. Rindo targets EGFR. Only about 30% of GBM patients have the EGFR "lock" to Rindo's "Key". When you see trials like this and others with pre-selected single or (couple) antigens fail, it provides more strength to the argument to use "PATIENT SPECIFIC" whole tumor(s) Lysate. Not only are there multiple targets(potentially 1000's), they are specific to each individual patients' tumor and tumors with multiple injection via direct. Since even intratumor heterogeneity among patients is observed, the multiple injection approach of Direct makes sense to me amd I am excited about Method B and multiple injections/lesions.